source
- FDA rejects ITM radiopharma therapy while WHO defends immunization schedulesThe U.S. Food and Drug Administration has issued a rejection of a radiopharmaceutical therapy identified as ITM, indicating that the product did not meet the agency's requirements for approval. Th…
- Dr Parikh on the Feasibility and Importance of Immunotherapy Trials in Anal CancerAparna R. Parikh, MD, discusses how trials like PODIUM-303 are reshaping the treatment paradigm for squamous cell anal carcinomas.onclive · 3mo ago↗ source